A5024550421- Prostate Cancer Treatment and Research
- Angiogenesis and VEGF in Cancer
- Medical Imaging and Pathology Studies
- Cancer Diagnosis and Treatment
- Zebrafish Biomedical Research Applications
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Receptor Mechanisms and Signaling
- Colorectal Cancer Treatments and Studies
Champalimaud Foundation
2017-2020
Abstract Despite promising preclinical results, average response rates to anti-VEGF therapies, such as bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side effects. Currently, there no biomarkers available select patients that can benefit from this therapy. Depending on the individual tumor, therapies either block or promote metastasis. In context, an assay able predict responses prior treatment, including impact metastasis would prove of great value guide...
Metastatic prostate cancer recurrence after definitive local therapy can occur in any tissue.Usually, the first affected site is bone.Lung metastases without bone or lymph node involvement are extremely rare patients with cancer, and only a handful of cases reported literature.In several other malignancies, such as breast sarcomas, colorectal renal cell carcinoma, long-term disease-free survival has been resection solitary pulmonary metastases.We present three unusual isolated initial...
e15743 Background: NG is a standard 1 st line treatment for APC. Although recommended in 2 nd after FOLFIRINOX, there little evidence of its efficacy, tolerability and markers efficacy. Methods: We performed multicenter retrospective cohort study, including patients (pts) with APC from 5 centers Portugal treated FOLFIRINOX 01/2013-12/2016. collected demographic, clinicopathological characteristics data. used descriptive statistics, Kaplan-Meier methods Cox proportional hazards analysis....